5-year outcomes of bictegravir-emtricitabine-tenofovir alafenamide (B-F-TAF) as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and/or low CD4 cell count in two Phase 3 randomised clinical trials

Abstract

Abstract is not available.